Loading

JSM Clinical Oncology and Research

Prognostic Value of Parapharyngeal Involvement Subclassifications Divided by Parapharyngeal Muscles in Nasopharyngeal Carcinoma: A Study of 1752 Patients from Two Centers

Research Article | Open Access | Volume 12 | Issue 1

  • 1. Department of Laboratory Medicine, the Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou 510630, China
  • 2. Radiotherapy Department of Nasopharyngeal Carcinoma, Cancer Center, The First People’s Hospital of Foshan Affiliated to Sun Yat-sen University, Foshan 528000, China
  • 3. Department of Radiology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangzhou 510060, China
  • 4. Department of Radiology, the Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou 510630, China
  • 5. Department of Radiation Oncology, the Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou 510630, China
  • #. These authors contributed equally to this work
+ Show More - Show Less
Corresponding Authors
Xiao-Hong Wang, Department of Radiology, the Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China. Tel: +86-20-85253108 Fax: +86-20-85253336 Shao-Bo Liang, Department of Radiation Oncology, the Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China. Tel: +86-20-85253530 Fax: +86-20-85253336
Abstract

Background: Parapharyngeal Involvement (PI) is common in local invasion but with different degrees in Nasopharyngeal Carcinoma (NPC). This study firstly assessed the prognostic value of PI subclassifications divided by parapharyngeal muscles in NPC.

Methods: 1,752 newly diagnosed NPC patients from two centers were enrolled. The involvement of parapharyngeal muscles including Levator Veli Palatine Muscle (LVPMI), Tensor Veli Palatine Muscle (TVPMI), medial pterygoid muscle (MPMI) and Lateral Pterygoid Muscle (LPMI) was diagnosed by Magnetic Resonance Imaging (MRI). Univariate and multivariate models were constructed to assess the association between PI and survival.

Results: The Progression-Free Survival (PFS), Overall Survival (OS), Distant Metastasis-Free Survival (DMFS), and Locoregional Relapse-Free Survival (LRRFS) between No-PI and LVPMI were similar, p values were 0.446, 0.337, 0.372 and 0.446, respectively, similar to PFS, OS, DMFS and LRRFS between MPMI and LPMI. So PI subclassifications were divided into four degrees: No-PI/LVPMI, TVPMI, MPMI/LPMI, and (infratemporal fossa involvement, IFI). The survival curves among four degrees were statistically different (p < 0.05), except for PFS, OS, and LRRFS between grade 3 and grade 4. Multivariate analyses indicated PI degree (grade 1/2 vs. grade 3/4) was an independent prognostic factor of PFS, OS, DMFS and LRRFS (p < 0.05). If MPMI/LPMI was classified into the T3 stage, there were only 0.6% (10/1,752) incidence rates changing in T2 or T3 stages, and the predictive value was without statistical difference (p > 0.05).

Conclusion: In NPC patients, it was feasible to divide PI by parapharyngeal muscles. The advanced PI predicted poorer survival outcomes than those with mild PI.

Keywords

• Nasopharyngeal carcinoma

• Parapharyngeal involvement subclassifications

• T stage; Prognosis

CITATION

Fu YC, Chen LS, Cui CY, Xie SD, Xu XY, et al. (2024) Prognostic Value of Parapharyngeal Involvement Subclassifications Divided by Parapharyngeal Muscles in Nasopharyngeal Carcinoma: A Study of 1752 Patients from Two Centers. JSM Clin Oncol Res 12(1): 1074.

ABBREVIATIONS

PI: Parapharyngeal Involvement; NPC: Nasopharyngeal Carcinoma; LVPMI: Levator Veli Palatine Muscle; TVPMI: Tensor Veli Palatine Muscle; MPMI: Medial Pterygoid Muscle; LPMI: Lateral Pterygoid Muscle; IFI: Infratemporal Fossa; MRI: Magnetic Resonance Imaging; PFS: Progression Free Survival; OS: Overall Survival; DMFS: Distant Metastasis-Free Survival; LRRFS: Locoregional Relapse-Free Survival; CT: Computed Tomography; 2D-RT: 2-Dimensional Radiotherapy; IMRT: Intensity-Modulated Radiation Therapy; AJCC: The American Joint Commission on Cancer staging system; PTV: Planning Target Volume; CTV: Clinical Target Volume; RT: Radiation Therapy

BACKGROUND

Nasopharyngeal Carcinoma (NPC) has a high incidence rate in South China, compared to a very low incidence rate in most part of the world [1-3]. Radiotherapy is the first and primary treatment strategy for non-metastatic NPC. Thus without pathology, tumor invasion of the anatomical structures around the nasopharynx is diagnosed by imaging. Magnetic Resonance Imaging (MRI), which has good soft tissue contrast resolution, is the best imaging technique for evaluating the extent of primary tumor in NPC [4-6].

As a highly malignant carcinoma, NPC is easy to infiltrate into the surrounding tissues, including bilateral invasion into the parapharyngeal space. According to our previous study, parapharyngeal muscles were at different risks of tumor invasion. The Levator Veli Palatine Muscle Involvement (LVPMI) And Tensor Veli Palatine Muscle Involvement (TVPMI) were at high risk, with incidence rates of 65.5% and 57.2%. Medial pterygoid muscle involvement (MPMI) and Lateral Pterygoid Muscle Involvement (LPMI) were at medium risk, with incidence rates of 19.9% and 10.6%. Infratemporal Fossa Involvement (IFI) was at low risk of tumor invasion, with incidence rate of 2.9% [7].

Due to the different risks of tumor invasion in the parapharynx, the prognostic value of Parapharyngeal Involvement (PI) subclassifications is a hotspot of researches. There have been some studies evaluating the degrees of PI based on different grading systems, such as Min’s classification, Sham’s classification, Xiao’s classification, and Heng’s classification [8-11]. These hypothetical lines were applicable in Computed Tomography (CT) era, but there were some limitations in dividing PI by hypothetical lines, such as most of them were established on CT and 2-Dimensional Radiotherapy (2D-RT) era, which might be not feasible in MRI and Intensity-Modulated Radiation Therapy (IMRT) era. and, the hypothetical lines were not visual and clear, so it was difficult to remember. Therefore, it might be more advantageous to divid PI to different degrees by parapharyngeal muscles than hypothetical lines.

In the 8th edition of the American Joint Commission on Cancer staging system (AJCC) of NPC, PI including TVPMI, MPMI or LPMI is classsified to T2 stage, and IFI is classsified to T4 stage [12]. However, there are still some controversies in the prognostic value of PI subclassifications in NPC. In Luo et al. study, the OS between patients with IFI was poorer than those with MPMI and/ or LPMI [13]. In Xiao et al. study, the prognosis of patients with LPMI and/or IFI were shown to be significantly worse than those affected only MPMI or the T3-stage disease [14]. It is suggested that PI subclassifications should be considered in future TNM staging revisions.

Thus, in this study, we comprehensively evaluated PI by MRI, and firstly divided PI to different degrees by parapharyngeal muscles in NPC patients on large samples from two centers. We aimed to evaluate the predictive value of this PI subclassification, to evaluate the current TNM staging and to make individualized treatment regimen for NPC patients.

METHODS

Patients

This study was approved by the Ethics Committees of the Third Affiliated Hospital of Sun Yat-Sen University, and the need for informed consent was waived because of the retrospective nature. This study enrolled 1,752 patients with NPC, who were treated from January 2010 to March 2014. Among them, 1,320 patients were treated at Sun Yat-sen University Cancer Center, and 432 patients were treated First People’s Hospital of Foshan Affiliated to Sun Yat-sen University. The inclusion criteria were newly diagnosed, histologically proven, and non-metastatic NPC, prior history of malignant tumors, pretreatment MRI of the nasopharynx and neck, and complete records of clinical data.

All patients included 1,297 men and 455 women (male:female ratio, 2.8:1), with a median age of 46 years (range, 11-80 years). All the patients were restaged according to the 8th edition of the AJCC system [12]. The stage distribution was as follows: 437/1,752 (24.9%) with T1, 227 (13%) with T2, 678 (38.7%) with T3, and 410 (23.4%) with T4; 352 (20.1) with N0, 993 (56.7%) with N1, 289 (16.5%) with N2, and 118 (6.7%) with N3; and 145 (8.3%) with stage I, 394 (22.5%) with stage II, 708 (40.4%) with stage III, and 505 (28.8%) with stage IVa.

Imaging

Before treatment, all patients underwent MRI of the nasopharynx and neck with a 1.5-T or 3.0-T MRI system. Detailed protocol of the MRI scan has been previously described in the reported studies [15,16]. After receiving a head-and-neck combined coil, patients first underwent non-contrast-enhanced T1-Weighted Imaging (T1WI) and T2-Weighted Imaging (T2WI) in the axial, coronal, and sagittal planes. Contrast-enhanced images were then acquired after intravenous injection of contrast agent (Gd-DTPA; 0.1 mmol/kg). The T1WI parameters were FSE, TR = 500–600 ms, and TE = 10–20 ms; the T2WI parameters were FSE, TR = 4000–6000 ms, and TE = 95–110 ms. Section thickness was 5 mm for the axial and coronal planes and 3–4 mm for the sagittal plane; slice gap was 1 mm.

Two radiologists with >10 years’ experience in head and neck carcinomas independently evaluated the MRI scans, and any disagreements were resolved by consensus every two weeks. The PI subclassifications were divided by parapharyngeal muscles, including No-PI, LVPMI, TVPMI, MPMI, LPMI and IFI (Figure 1).

Figure 1: Axial T2-weighted magnetic resonance (MR) image at the level of  the nasopharynx shows the parapharyngeal subclassifications as defined with  anatomic criteria. LVPMI = levator veli palatine muscle, TVPMI = tensor veli  palatine muscle, MPMI = medial pterygoid muscle, LPMI = lateral pterygoid  muscle, IF = infratemporal fossa.

Figure 1: Axial T2-weighted magnetic resonance (MR) image at the level of the nasopharynx shows the parapharyngeal subclassifications as defined with anatomic criteria. LVPMI = levator veli palatine muscle, TVPMI = tensor veli palatine muscle, MPMI = medial pterygoid muscle, LPMI = lateral pterygoid muscle, IF = infratemporal fossa.

The parapharyngeal muscle involvement was diagnosed as follows: 1) the muscle was not distinguishable from the tumor mass, 2) asymmetry in signal intensity existed, 3) the integrity of the muscles of mastication had been disrupted by the tumor [13]. IFI was defined as extension beyond the anterior surface of the LPM or lateral extension beyond the posterolateral wall of the maxillary sinus or pterygomaxillary fissure [17].

Treatment

All patients were treated using IMRT, of which the detailed protocol had been described in the previous reports [18,19]. For Planning Target Volume (PTV) of the primary tumor plus metastatic retropharyngeal lymph nodes, metastatic cervical lymph nodes, high-risk Clinical Target Volume (CTV), and low- risk CTV, the prescribed doses were 66-72 Gy/30-33 fractions, 64-70 Gy/30-33 fractions, 60-63 Gy/30-33 fractions and 50-56 Gy/28-33 fractions, respectively. The Radiation Therapy (RT) was given one fraction daily, and 5 days weekly.

In total, 1,450 patients (1,450/1,752, 82.8%) with locoregionally advanced disease received platinum-based chemotherapy. Of these, 892 received induction chemotherapy plus concurrent chemotherapy, and 558 received concurrent chemotherapy. The induction chemotherapy composed 2-3 cycles of PF, TPF, TP, or GP regimens every three weeks, and concurrent chemotherapy included cisplatin weekly or every three weeks.

The prescription doses had been described in the previous reports [20,21]. In the event of tumor relapse or persistent disease, salvage treatment such as surgery, radiotherapy, or chemotherapy was administered when appropriate.

Follow-up and statistical analysis

Patients were followed up every three months during the first two years after RT and every six months thereafter. The main endpoint was Progression-Free Survival (PFS), which was calculated from the date of starting treatment to the date of disease progress, or death due to any reasons, or last follow-up. The secondary endpoints included Overall Survival (OS), Distant Metastasis-Free Survival (DMFS), and Locoregional Relapse-Free Survival (LRRFS), which were also calculated as above.

All analyses were performed using SPSS 22.0 (IBM Corp, Armonk, NY, USA). Chi-square or Fisher exact test was used to compare categorical data. Univariate analyses were conducted using the Kaplan–Meier method. Multivariable analyses were performed using the Cox proportional hazards model, in which the following parameters were included: age (≤45 years vs. >45 years), gender (male vs. female), chemotherapy (yes vs. no), N category (N0-1 vs. N2-3), skull base involvement (yes vs. no), paranasal sinuses involvement (yes vs. no), intracranial involvement (yes vs. no), orbital involvement (yes vs. no). Two- sided p values < 0.05 were considered statistically significant.

RESULTS

The incidence rates of PI subclassifications

Of the total 1,752 NPC patients recruited, the incidence rates of No-PI, LVPMI, TVPMI, MPMI, LPMI and IFI were 25.5%, 73.9%,58.5%, 18.3%, 8.5%, and 2.8%, respectively. When the degrees of PI were divided by parapharyngeal muscles, the incidence rates of PI subclassifications including No-PI, LVPMI, TVPMI, MPMI, LPMI, and IFI were 25.5%, 15.7%, 40.1%, 9.8%, 6.2%, and 2.8%, respectively. The distribution of PI in T stages was shown in Table 1. It was shown that the more severe PI, the more advanced in the T stages. And it was also shown that most patients with MPMI and/or LPMI were accompanied with stage T3/T4 factors.

Table 1: The distribution of different degrees of parapharyngeal invasion in T stages in 1752 patients with nasopharyngeal carcinoma.

Tumorl Invasion

T1

T2

T3

T4

In Total

No-PI,n (%)

357 (80%)

4 (0.9%)

78 (17.5%)

7 (1.6%)

446 (100%)

LVPMI, n (%)

80 (29.1%)

63 (22.9%)

118 (42.9%)

14 (5.1%)

275 (100%)

TVPMI, n (%)

0

150 (21.4%)

395 (56.3%)

157 (22.4%)

702 (100%)

MPMI, n (%)

0

10 (5.8%)

75 (43.9%)

86 (50.3%)

171 (100%)

LPMI, n (%)

0

0

12 (11%)

97 (89%)

109 (100%)

IFI, n (%)

0

0

0

49 (100%)

49 (100%)

Abbreviations: No-PI: No Parapharyngeal Involvement; LVPMI: Levator Veli Palatine Muscle Involvement; TVPMI: Tensor Veli Palatine Muscle Involvement; MPMI: Medial Pterygoid Muscle Involvement; LPMI: Lateral Pterygoid Muscle Involvement; IFI: Infratemporal Fossa Involvement

Prognostic value of parapharyngeal muscles

The estimated 5-year PFS rates in patients with No-PI, LVPMI, TVPMI, MPMI, LPMI and IFI were 87.8%, 85.4%, 73.8%, 62.6%,63.2%, and 49.9%; The estimated 5-year OS rates were 94.2%, 92.5%, 83.2%, 73%, 72%, and 60.3%; 5-year DMFS rates were 93%, 90.7%, 85.1%, 77.9%, 77.4%, and 60.8%; and 5-year LRRFS rates were 95.1%, 94.8%, 88.3%, 83%, 82.8%, and 72.8%, respectively (Figure 2).

Figure 2 Prognostic comparison of 1,752 NPC patients among different parapharyngeal involvement subclassifications. (A) Progression-free  survival, (B) Overall survival, (C) Distant metastasis-free survival, (D) Locoregional relapse-free survival.

Figure 2: Prognostic comparison of 1,752 NPC patients among different parapharyngeal involvement subclassifications. (A) Progression-free survival, (B) Overall survival, (C) Distant metastasis-free survival, (D) Locoregional relapse-free survival.

Univariate analyses indicated PFS, OS, DMFS, and LRRFS between No-PI and LVPMI were similar, p values were 0.446, 0.337, 0.372, and 0.446, respectively. Similar to PFS, OS, DMFS, and LRRFS between MPMI and LPMI, p values were 0.859, 0.698, 0.729, and 0.859, respectively.

Prognostic value of PI subclassifications divided by parapharyngeal muscles

According to the above analysis, the degrees of PI were classified into four degrees: grade 1 (No-PI or LVPMI), grade 2 (TVPMI), grade 3 (MPMI or LPMI), and grade 4 (IFI). The incidence rates of these 4 degrees were 41.2%, 40.1%, 16%, and 2.8%, respectively. The estimated 5-year PFS rates in patients with grade 1, grade 2, grade 3, and grade 4 were 86.6%, 73.8%, 62.8%, and 49.9%; The estimated 5-year OS rates were 93.6%, 83.2%, 72.7%, and 60.3%; 5-year DMFS rates were 92.1%,85.1%, 77.7%, and 60.8%; and 5-year LRRFS rates were 95%,88.3%, 82.9%, and 72.8%, respectively (Figure 3).

Figure 3 Prognostic comparison of 1,752 NPC patients among four different grades of parapharyngeal involvement. (A) Progression-free survival,  (B) Overall survival, (C) Distant metastasis-free survival, (D) Locoregional relapse-free survival.

Figure 3: Prognostic comparison of 1,752 NPC patients among four different grades of parapharyngeal involvement. (A) Progression-free survival, (B) Overall survival, (C) Distant metastasis-free survival, (D) Locoregional relapse-free survival.

The survival curves among four degrees were statistically different (p < 0.05), except that the PFS, OS, and LRRFS between grade 3 and grade 4 were close to statistical difference, p values were 0.071, 0.078, and 0.101. The negative results might lie in the small patients’number in grade 4 (N=49). The sociodemographic and clinical characteristics of 1,752 NPC patients were shown in table 2. Multivariate analyses indicated that the degree of PI (grade 1/ grade 2 vs. grade 3/grade 4) was an independent predictor of PFS, OS, DMFS, and LRRFS (all p < 0.001, Table 3).

Table 2: Sociodemographic and clinical characteristics of the participants

Variables

Numbers

PFS

 

OS

 

DMFS

 

LRRFS

 

 

N=1752 (100%)

surv.

P value

surv.

P value

surv.

P value

surv.

P value

Sex (%)

 

 

0.381

 

0.006

 

0.338

 

0.571

Male

1297 (74%)

76.2%

 

84%

 

85.7%

 

90.6%

 

Female

455 (26%)

78.3%

 

89%

 

87.7%

 

89.2%

 

Age (years)

 

 

0.085

 

< 0.001

 

0.429

 

0.444

≤ 45

858 (49%)

78.7%

 

89.3%

 

87%

 

90.3%

 

> 45

894 (51%)

74.8%

 

81.4%

 

85.5%

 

88.9%

 

N category (%)

 

 

< 0.001

 

< 0.001

 

< 0.001

 

0.001

N0-1

1345 (76.8%)

80.8%

 

88.9%

 

89.8%

 

91.3%

 

N2-3

407 (23.2%)

63%

 

72.9%

 

74.2%

 

84.8%

 

Chemotherapy

 

 

0.157

 

0.551

 

0.024

 

0.065

Yes

1449 (82.7%)

76%

 

85.1%

 

85.4%

 

89.2%

 

No

303 (17.3%)

80%

 

86.3%

 

90.6%

 

93.5%

 

Skull base involvement

 

< 0.001

 

< 0.001

 

< 0.001

 

< 0.001

Yes

1079 (61.6%)

71.4%

 

81%

 

83.2%

 

87.2%

 

No

673 (38.4%)

84.9%

 

91.8%

 

91%

 

93.9%

 

Paranasal sinuses involvement

 

< 0.001

 

< 0.001

 

< 0.001

 

< 0.001

Yes

442 (25.2%)

64.3%

 

74.7%

 

75.2%

 

83.4%

 

No

1310 (74.8%)

80.7%

 

88.6%

 

88.7%

 

91.9%

 

Intracranial involvement

 

< 0.001

 

< 0.001

 

< 0.001

 

0.007

Yes

341 (19.5%)

62.7%

 

71.5%

 

77.1%

 

85.1%

 

No

1411 (80.5%)

80%

 

88.4%

 

88.3%

 

91%

 

Orbital involvement

 

 

0.009

 

< 0.001

 

0.015

 

0.741

Yes

95 (5.4%)

65.2%

 

70.4%

 

77%

 

88.7%

 

No

1657 (94.6%)

77.3%

 

86.1%

 

86.8%

 

90%

 

Parapharyngeal involvement

 

< 0.001

 

< 0.001

 

< 0.001

 

< 0.001

G1-2

1423 (81.2%)

80.4%

 

88.5%

 

88.7%

 

91.8%

 

G3-4

329 (18.8%)

60.9%

 

70.8%

 

75.2%

 

81.5%

 

Abbreviations: OS: Overall Survival; PFS: Progress-Free Survival; DMFS: Distant Metastasis-Free Survival; LRRFS: Locoregional Relapse-Free Survival; G1-2: No Parapharyngeal Involvement or Levator Veli Palatine Muscle Involvement or Tensor Veli Palatine Muscle Involvement; G3-4, Medial Pterygoid Muscle Involvement or Lateral Pterygoid Muscle Involvement or Infratemporal Fossa Involvement

Table 3: Significant factors included in the multivariate analyses for 1,752 patients with nasopharyngeal carcinoma

Endpoint

Variable

HR

95% CI

P Value a

PFS

N category b

2.032

1.649 - 2.503

< 0.001

 

Parapharyngeal involvement

1.662

1.314 - 2.101

< 0.001

 

Skull base involvement

1.401

1.074 - 1.827

0.013

 

Paranasal sinuses involvement

1.433

1.132 - 1.812

0.003

OS

Age

1.650

1.270 - 2.142

< 0.001

 

Sex

1.389

1.007 - 1.916

0.046

 

N category b

2.404

1.860 - 3.108

< 0.001

 

Parapharyngeal involvement

1.987

1.496 - 2.640

< 0.001

 

Skull base involvement

1.512

1.061 - 2.155

0.022

 

Paranasal sinuses involvement

1.475

1.104 - 1.970

0.009

DMFS

N category b

2.598

1.991 - 3.390

< 0.001

 

Parapharyngeal involvement

1.941

1.444 - 2.610

< 0.001

 

Paranasal sinuses involvement

1.436

1.075 - 1.919

0.014

LRRFS

N category b

1.644

1.177 - 2.298

0.004

 

Parapharyngeal involvement

1.965

1.371 - 2.816

< 0.001

 

Paranasal sinuses involvement

1.754

1.238 - 2.486

0.002

Abbreviations: HR: Hazard Ratio; CI: Confidence Interval; OS: Overall Survival; PFS: Progress-Free Survival; DMFS: Distant Metastasis-Free Survival; LRRFS: Locoregional Relapse-Free Survivala P-values were calculated using an adjusted Cox proportional hazards model. b According to the 8th AJCC staging system.

The impact of PI subclassifications in T stages

The estimated 5-year PFS rates in patients with T1, T2, T3, and T4 stages were 88.1%, 79%, 75.4%, and 65.2%; The estimated 5-year OS rates were 95.2%, 85.9%, 85.2%, and 74.1%; 5-year DMFS rates were 93.4%, 86.1%, 86.2%, and 78.4%; and 5-year LRRFS rates were 95.1%, 91.8%, 87.9%, and 86.1%, respectively.

The survival curves of PFS, OS, DMFS and LRRFS between T2 and T3 stages were close, p values were 0.354 (Figure 4A), 0.908, 0.889 and 0.186 (Figure 4B).

Figure 4 Prognostic comparison of 1,752 NPC patients among different T staging systems. (A) Progression-free survival in current-T stages, (B)  Lcoregional relapse-free survival in current-T stages, (C) Progression-free survival in new-T stages, (D) Lcoregional relapse-free survival in new-T  stages.

Figure 4: Prognostic comparison of 1,752 NPC patients among different T staging systems. (A) Progression-free survival in current-T stages, (B) Lcoregional relapse-free survival in current-T stages, (C) Progression-free survival in new-T stages, (D) Lcoregional relapse-free survival in new-T stages.

If MPMI/LPMI was classified into T3 stage, the incidence rates of new T2 and T3 stages were 12.4% (217/1,752) and 39.3% (688/1,752). There were only 0.6% (10/1,752) incidence rates changing in T2 or T3 stages. And the 5-year PFS, OS, DMFS and LRRFS rates between patients with new T2 and T3 stages were 81% vs. 74.8% (Figure 4C, p = 0.119), 87.2% vs. 84.7% (p = 0.462), 87.9% vs. 85.6% (p = 0.521), 87.9% vs. 85.6% (Figure 4D, p = 0.066).

DISCUSSION

In the present study, PI subclassifications were divided by parapharyngeal muscles, including grade 1 (No-PI or LVPMI), grade 2 (TVPMI), grade 3 (MPMI or LPMI), and grade 4 (IFI). The incidence rates of these 4 degrees were 41.2%, 40.1%, 16%, and 2.8%, respectively. The survival curves among four degrees were statistically different (p < 0.05), except for the PFS, OS, and LRRFS between grade 3 and grade 4. The degree of PI (grade 1/grade 2 vs. grade 3/grade 4) was an independent predictor of PFS, OS, DMFS, and LRRFS (all p < 0.001). If MPMI/LPMI was classified into the T3 stage, there were only 0.6% (10/1,752) incidence rates changing in T2 or T3 stages, and the predictive value was without statistical difference (p > 0.05).

In this study, the incidence rates of LVPMI, TVPMI, MPMI, LPMI, and IFI were 73.9%, 58.5%, 18.3%, 8.5%, and 2.8%,respectively. These incidence rates were similar to our previously reported data [5]. In the study by Dong et al., the incidence rates of LVPMI, TVPMI, MPMI, LPMI, and IFI were 74.0%, 55.8%, 19.5%,8.2%, and 2.8%, respectively [17]. In this study, it was also shown that the more severe in PI, the more advanced in the T stages, and most of patients with MPMI and/or LPMI was accompanied with stage T3/T4 factors.

In the present study, PI subclassifications were divided by parapharyngeal muscles, including grade 1 (No-PI or LVPMI), grade 2 (TVPMI), grade 3 (MPMI or LPMI), and grade 4 (IFI). The survival curves among four degrees were statistically different (p< 0.05), except the PFS, OS, and LRRFS between grade 3 and grade 4, which were close to statistical difference. The PI degree was an independent prognostic factor of PFS, OS, DMFS and LRRFS. In Huang et al. study, PI was separated into four invasion patterns: pattern A (only post-styloid space), pattern B (post-styloid space, CS extension), pattern C (poststyloid space, pre-styloid space extension), and pattern D (all spaces), which was recommended to optimize T3 heterogeneity [22]. Compared to the reported reports, this grading system was based on parapharyngeal muscles which might be more inherent and clear, and could be easily diagnosed by MRI. Furthermore, this study also confirmed that advanced PI indicated poorer outcomes than those with mild PI, as the results in the previous classification [23].

In this study, if MPMI/LPMI was classified into T3 stage, there were only 0.6% incidence rates changing in T2 or T3 stages, and the predictive value was without statistical difference. In Tang et al. study, when masticator space involvement included MPMI and LPMI, the disease was suggested to be classified as T4 stage [24]. In Zhang et al. study, MPMI could be graded as T2 stage, and LPMI/IFI as T4 stage [25]. In Sze et al. study, NPC with MPMI and/or LPMI alone should be classified as the T2 disease [26]. Based on the controversial resultss, the impact of MPMI/LPMI in T stages should be reassessed in future TNM stages.

To our knowledge, this study is the first study to divide PI by parapharyngeal muscles based on a large sample from two centers. However, our study has some limitations. First, due to the nature of retrospective studies, chemotherapy regimens were diverse, despite this, the treatment outcomes among these regimens were similar according to previous reports [27-29].

Second, the incidence rates of IFI were so low that it might lead to false negative results of survival comparison, so it needed to enroll larger samples in further studies.

CONCLUSION

In summary, in NPC patients, it was feasible to divide PI by parapharyngeal muscles. The advanced PI predicted poorer survival outcomes than those with mild PI. The prognostic value of PI subclassifications divided by parapharyngeal muscles should be reassessed with larger samples in future TNM staging revisions.

Acknowledgement: Not applicable

AUTHOR CONTRIBUTIONS

SBL and XHW was responsible for the study design. YCF was the major contributor in writing the manuscript. LSC and CYC collected the patient data. SDX was responsible for the statistical data. XYX and XHW performed the follow examination. All authors read and approved the final manuscript.

FUNDING

This work was supported by the Science and Technology Bureau of Guangzhou  [No. 202201010847]; and the Third Affiliated Hospital of Sun Yat-sen University [No. 2023GZRPYMS14]. The funding provided the resources for the study design, data collection and data analysis, and manuscript polish.

Availability of Data and Materials: Not applicable.

DECLARATIONS

Ethics approval and consent to participate

This study was approved by the Ethics Committees of the Third Affiliated Hospital of Sun Yat-Sen University, and the need for written informed consent was waived.

Consent for Publication: Not applicable.

COMPETING INTERESTS

The authors declare that they have no competing interest.

REFERENCES
  1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021; 71: 209-249.
  2. Zhang LF, Li YH, Xie SH, Ling W, Chen SH, Liu Q, et al. Incidence trend of nasopharyngeal carcinoma from 1987 to 2011 in Sihui county, Guangdong province, South China: An age-period-cohort analysis. Chin J Cancer. 2015; 34: 350-357.
  3. Ji MF, Sheng W, Cheng WM, Ng MH, Wu BH, Yu X, et al. Incidence and mortality of nasopharyngeal carcinoma: Interim analysis of a cluster randomized controlled screening trial (PRO-NPC-001) in southern China. Ann Oncol. 2019; 30: 1630-1637.
  4. Liao XB, Mao YP, Liu LZ, Tang LL, Sun Y, Wang Y, et al. How does magnetic resonance imaging influence staging according to AJCC staging system for nasopharyngeal carcinoma compared with computed tomography? Int J Radiat Oncol Biol Phys. 2008; 72: 1368- 1377.
  5. Luo X, Liao W, He Y, Tang F, Wu M, Shen Y, et al. Deep learning- based accurate delineation of primary gross tumor volume of nasopharyngeal carcinoma on heterogeneous magnetic resonance imaging: A large-scale and multi-center study. Radiother Oncol. 2023; 180: 109480.
  6. Liao W, He J, Luo X, Wu M, Shen Y, Li C, et al. Automatic delineation of gross tumor volume based on magnetic resonance imaging by performing a novel semisupervised learning framework in nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys. 2022; 113: 893-902.
  7. Liang SB, Sun Y, Liu LZ, Chen Y, Chen L, Mao YP, et al. Extension of local disease in nasopharyngeal carcinoma detected by magnetic resonance imaging: Improvement of clinical target volume delineation. Int J Radiat Oncol Biol Phys. 2009; 75: 742-750.
  8. Min H, Hong M, Ma J, Zhang E, Zheng Q, Zhang J, et al. A new staging system for nasopharyngeal carcinoma in China. Int J Radiat Oncol Biol Phys. 1994; 30: 1037-1042.
  9. Heng DM, Wee J, Fong KW, Lian LG, Sethi VK, Chua ET, et al. Prognostic factors in 677 patients in singapore with nondisseminated nasopharyngeal carcinoma. Cancer. 1999; 86: 1912-1920.
  10. Sham JS, Choy D. Prognostic value of paranasopharyngeal extension of nasopharyngeal carcinoma on local control and short-term survival. Head Neck. 1991;13:298-310.
  11. Xiao GL, Cai WM, Xu GZ. Influence of abnormality in parapharyngeal space by CT scans on T staging of nasopharyngeal carcinoma. Chinese J Radiat Oncol. 1993; 2: 2-3.
  12. Amin MB, Edge S, Editors. AJCC Cancer Staging Manual. 8th ed. New York. Springer. 2017.
  13. Luo DH, Yang J, Qiu HZ, Shen T, Chen QY, Huang PY, et al. A new T classification based on masticator space involvement in nasopharyngeal carcinoma: A study of 742 cases with magnetic resonance imaging. BMC Cancer. 2014; 14: 653.
  14. Xiao Y, Pan J, Chen Y, Lin S, Chen Y, Zong J, et al. Prognostic value of MRI-derived masticator space involvement in IMRT-treated nasopharyngeal carcinoma patients. Radiat Oncol. 2015; 10: 204.
  15. Wang XY, Zhu SY, Wu WJ, Li HJ, Li J, Lin XF, et al. Extent of paranasal sinus involvement and its prognostic value in nasopharyngeal carcinoma: Proposed modification in the current UICC/AJCC staging system. Radiother Oncol. 2021; 160: 221-227.
  16. Liang SB, Chen LS, Chen HY, Yang XL, Wang DH, Cui CY, et al. Prognostic influence of prevertebral space involvement in nasopharyngeal carcinoma: A retrospective study. Radiother Oncol. 2021; 156: 113-119.
  17. Dong A, Huang W, Ma H, Cui C, Zhou J, Ruan G, et al. Grading soft tissue involvement in nasopharyngeal carcinoma using network and survival analyses: A two-center retrospective study. J Magn Reson Imaging. 2021; 53: 1752-1763.
  18. Zhao C, Miao JJ, Hua YJ, Wang L, Han F, Lu LX, et al. Locoregional control and mild late toxicity after reducing target volumes and radiation doses in patients with locoregionally advanced nasopharyngeal carcinoma treated with induction chemotherapy (IC) followed by concurrent chemoradiotherapy: 10-year results of a phase 2 study. Int J Radiat Oncol Biol Phys. 2019; 104: 836-844.
  19. Liang SB, Wang Y, Hu XF, He SS, Yang XL, Liu LZ, et al. Survival and toxicities of IMRT based on the RTOG protocols in patients with nasopharyngeal carcinoma from the endemic regions of China. J Cancer. 2017; 8: 3718-3724.
  20. Liang SB, Chen LS, Yang XL, Chen DM, Wang DH, Cui CY, et al. Influence of tumor necrosis on treatment sensitivity and long-term survival in nasopharyngeal carcinoma. Radiother Oncol. 2021; 155: 219-225.
  21. Luo WJ, Zou WQ, Liang SB, Chen L, Zhou GQ, Peng H, et al. Combining tumor response and personalized risk assessment: Potential for adaptation of concurrent chemotherapy in locoregionally advanced nasopharyngeal carcinoma in the intensity-modulated radiotherapy era. Radiother Oncol. 2021; 155: 56-64.
  22. Huang W, Quan T, Zhao Q, Li S, Cai Y, Zhou J, et al. MRI of nasopharyngeal carcinoma: Parapharyngeal subspace involvement has prognostic value and influences T-staging in the IMRT era. Eur Radiol. 2022; 32: 262-271.
  23. Huang PY, Sun ZY, Xie CM, Chen QY, Wen YF, Li J, et al. Prognostic significance of the various classifications for parapharyngeal space involvement in nasopharyngeal carcinoma. Acta Otolaryngol. 2012; 132: 1197-1207.
  24. Tang LL, Li WF, Chen L, Sun Y, Chen Y, Liu LZ, et al. Prognostic value and staging categories of anatomic masticator space involvement in nasopharyngeal carcinoma: A study of 924 cases with MR imaging. Radiology. 2010; 257 :151-157.
  25. Zhang GY, Huang Y, Cai XY, Chen XP, Xu T, Wu J, et al. Prognostic value of grading masticator space involvement in nasopharyngeal carcinoma according to MR imaging findings. Radiology. 2014; 273: 136-143.
  26. Sze H, Chan LL, Ng WT, Hung AW, Lee MC, Chang AT, et al. Should all nasopharyngeal carcinoma with masticator space involvement be staged as T4? Oral Oncol. 2014; 50: 1188-1195.
  27. Chan SK, Chan SY, Tong CC, Lam KO, Kwong DL, Leung TW, et al. Comparison of efficacy and safety of three induction chemotherapy regimens with gemcitabine plus cisplatin (GP), cisplatin plus fluorouracil (PF) and cisplatin plus capecitabine (PX) for locoregionally advanced previously untreated nasopharyngeal carcinoma: A pooled analysis of two prospective studies. Oral Oncol. 2021; 114: 105158.
  28. Wang Y, Wang C, He S, Bai L, Kong F, Wang S, et al. Induction chemotherapy regimen of docetaxel plus cisplatin versus docetaxel, cisplatin plus fluorouracil followed by concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: Preliminary results of an open-label, noninferiority, multicentre, randomised, controlled phase 3 trial. EclinicalMedicine. 2022; 53: 101625.
  29. Wang L, Wu Z, Cheng W, Xie D, Lin F, Xia L, et al. Efficacy of concurrent chemoradiotherapy in subgroups of stage III nasopharyngeal carcinoma: An analysis based on 10-year follow-up. Radiat Oncol. 2021; 16: 215.

Fu YC, Chen LS, Cui CY, Xie SD, Xu XY, et al. (2024) Prognostic Value of Parapharyngeal Involvement Subclassifications Divided by Parapharyngeal Muscles in Nasopharyngeal Carcinoma: A Study of 1752 Patients from Two Centers. JSM Clin Oncol Res 12(1): 1074.

Received : 11 Jun 2024
Accepted : 21 Jun 2024
Published : 24 Jun 2024
Journals
Annals of Otolaryngology and Rhinology
ISSN : 2379-948X
Launched : 2014
JSM Schizophrenia
Launched : 2016
Journal of Nausea
Launched : 2020
JSM Internal Medicine
Launched : 2016
JSM Hepatitis
Launched : 2016
JSM Oro Facial Surgeries
ISSN : 2578-3211
Launched : 2016
Journal of Human Nutrition and Food Science
ISSN : 2333-6706
Launched : 2013
JSM Regenerative Medicine and Bioengineering
ISSN : 2379-0490
Launched : 2013
JSM Spine
ISSN : 2578-3181
Launched : 2016
Archives of Palliative Care
ISSN : 2573-1165
Launched : 2016
JSM Nutritional Disorders
ISSN : 2578-3203
Launched : 2017
Annals of Neurodegenerative Disorders
ISSN : 2476-2032
Launched : 2016
Journal of Fever
ISSN : 2641-7782
Launched : 2017
JSM Bone Marrow Research
ISSN : 2578-3351
Launched : 2016
JSM Mathematics and Statistics
ISSN : 2578-3173
Launched : 2014
Journal of Autoimmunity and Research
ISSN : 2573-1173
Launched : 2014
JSM Arthritis
ISSN : 2475-9155
Launched : 2016
JSM Head and Neck Cancer-Cases and Reviews
ISSN : 2573-1610
Launched : 2016
JSM General Surgery Cases and Images
ISSN : 2573-1564
Launched : 2016
JSM Anatomy and Physiology
ISSN : 2573-1262
Launched : 2016
JSM Dental Surgery
ISSN : 2573-1548
Launched : 2016
Annals of Emergency Surgery
ISSN : 2573-1017
Launched : 2016
Annals of Mens Health and Wellness
ISSN : 2641-7707
Launched : 2017
Journal of Preventive Medicine and Health Care
ISSN : 2576-0084
Launched : 2018
Journal of Chronic Diseases and Management
ISSN : 2573-1300
Launched : 2016
Annals of Vaccines and Immunization
ISSN : 2378-9379
Launched : 2014
JSM Heart Surgery Cases and Images
ISSN : 2578-3157
Launched : 2016
Annals of Reproductive Medicine and Treatment
ISSN : 2573-1092
Launched : 2016
JSM Brain Science
ISSN : 2573-1289
Launched : 2016
JSM Biomarkers
ISSN : 2578-3815
Launched : 2014
JSM Biology
ISSN : 2475-9392
Launched : 2016
Archives of Stem Cell and Research
ISSN : 2578-3580
Launched : 2014
Annals of Clinical and Medical Microbiology
ISSN : 2578-3629
Launched : 2014
JSM Pediatric Surgery
ISSN : 2578-3149
Launched : 2017
Journal of Memory Disorder and Rehabilitation
ISSN : 2578-319X
Launched : 2016
JSM Tropical Medicine and Research
ISSN : 2578-3165
Launched : 2016
JSM Head and Face Medicine
ISSN : 2578-3793
Launched : 2016
JSM Cardiothoracic Surgery
ISSN : 2573-1297
Launched : 2016
JSM Bone and Joint Diseases
ISSN : 2578-3351
Launched : 2017
JSM Bioavailability and Bioequivalence
ISSN : 2641-7812
Launched : 2017
JSM Atherosclerosis
ISSN : 2573-1270
Launched : 2016
Journal of Genitourinary Disorders
ISSN : 2641-7790
Launched : 2017
Journal of Fractures and Sprains
ISSN : 2578-3831
Launched : 2016
Journal of Autism and Epilepsy
ISSN : 2641-7774
Launched : 2016
Annals of Marine Biology and Research
ISSN : 2573-105X
Launched : 2014
JSM Health Education & Primary Health Care
ISSN : 2578-3777
Launched : 2016
JSM Communication Disorders
ISSN : 2578-3807
Launched : 2016
Annals of Musculoskeletal Disorders
ISSN : 2578-3599
Launched : 2016
Annals of Virology and Research
ISSN : 2573-1122
Launched : 2014
JSM Renal Medicine
ISSN : 2573-1637
Launched : 2016
Journal of Muscle Health
ISSN : 2578-3823
Launched : 2016
JSM Genetics and Genomics
ISSN : 2334-1823
Launched : 2013
JSM Anxiety and Depression
ISSN : 2475-9139
Launched : 2016
Clinical Journal of Heart Diseases
ISSN : 2641-7766
Launched : 2016
Annals of Medicinal Chemistry and Research
ISSN : 2378-9336
Launched : 2014
JSM Pain and Management
ISSN : 2578-3378
Launched : 2016
JSM Women's Health
ISSN : 2578-3696
Launched : 2016
Clinical Research in HIV or AIDS
ISSN : 2374-0094
Launched : 2013
Journal of Endocrinology, Diabetes and Obesity
ISSN : 2333-6692
Launched : 2013
Journal of Substance Abuse and Alcoholism
ISSN : 2373-9363
Launched : 2013
JSM Neurosurgery and Spine
ISSN : 2373-9479
Launched : 2013
Journal of Liver and Clinical Research
ISSN : 2379-0830
Launched : 2014
Journal of Drug Design and Research
ISSN : 2379-089X
Launched : 2014
JSM Bioinformatics, Genomics and Proteomics
ISSN : 2576-1102
Launched : 2014
JSM Chemistry
ISSN : 2334-1831
Launched : 2013
Journal of Trauma and Care
ISSN : 2573-1246
Launched : 2014
JSM Surgical Oncology and Research
ISSN : 2578-3688
Launched : 2016
Annals of Food Processing and Preservation
ISSN : 2573-1033
Launched : 2016
Journal of Radiology and Radiation Therapy
ISSN : 2333-7095
Launched : 2013
JSM Physical Medicine and Rehabilitation
ISSN : 2578-3572
Launched : 2016
Annals of Clinical Pathology
ISSN : 2373-9282
Launched : 2013
Annals of Cardiovascular Diseases
ISSN : 2641-7731
Launched : 2016
Journal of Behavior
ISSN : 2576-0076
Launched : 2016
Annals of Clinical and Experimental Metabolism
ISSN : 2572-2492
Launched : 2016
Clinical Research in Infectious Diseases
ISSN : 2379-0636
Launched : 2013
JSM Microbiology
ISSN : 2333-6455
Launched : 2013
Journal of Urology and Research
ISSN : 2379-951X
Launched : 2014
Journal of Family Medicine and Community Health
ISSN : 2379-0547
Launched : 2013
Annals of Pregnancy and Care
ISSN : 2578-336X
Launched : 2017
JSM Cell and Developmental Biology
ISSN : 2379-061X
Launched : 2013
Annals of Aquaculture and Research
ISSN : 2379-0881
Launched : 2014
Clinical Research in Pulmonology
ISSN : 2333-6625
Launched : 2013
Journal of Immunology and Clinical Research
ISSN : 2333-6714
Launched : 2013
Annals of Forensic Research and Analysis
ISSN : 2378-9476
Launched : 2014
JSM Biochemistry and Molecular Biology
ISSN : 2333-7109
Launched : 2013
Annals of Breast Cancer Research
ISSN : 2641-7685
Launched : 2016
Annals of Gerontology and Geriatric Research
ISSN : 2378-9409
Launched : 2014
Journal of Sleep Medicine and Disorders
ISSN : 2379-0822
Launched : 2014
JSM Burns and Trauma
ISSN : 2475-9406
Launched : 2016
Chemical Engineering and Process Techniques
ISSN : 2333-6633
Launched : 2013
Annals of Clinical Cytology and Pathology
ISSN : 2475-9430
Launched : 2014
JSM Allergy and Asthma
ISSN : 2573-1254
Launched : 2016
Journal of Neurological Disorders and Stroke
ISSN : 2334-2307
Launched : 2013
Annals of Sports Medicine and Research
ISSN : 2379-0571
Launched : 2014
JSM Sexual Medicine
ISSN : 2578-3718
Launched : 2016
Annals of Vascular Medicine and Research
ISSN : 2378-9344
Launched : 2014
JSM Biotechnology and Biomedical Engineering
ISSN : 2333-7117
Launched : 2013
Journal of Hematology and Transfusion
ISSN : 2333-6684
Launched : 2013
JSM Environmental Science and Ecology
ISSN : 2333-7141
Launched : 2013
Journal of Cardiology and Clinical Research
ISSN : 2333-6676
Launched : 2013
JSM Nanotechnology and Nanomedicine
ISSN : 2334-1815
Launched : 2013
Journal of Ear, Nose and Throat Disorders
ISSN : 2475-9473
Launched : 2016
JSM Ophthalmology
ISSN : 2333-6447
Launched : 2013
Journal of Pharmacology and Clinical Toxicology
ISSN : 2333-7079
Launched : 2013
Annals of Psychiatry and Mental Health
ISSN : 2374-0124
Launched : 2013
Medical Journal of Obstetrics and Gynecology
ISSN : 2333-6439
Launched : 2013
Annals of Pediatrics and Child Health
ISSN : 2373-9312
Launched : 2013
JSM Clinical Pharmaceutics
ISSN : 2379-9498
Launched : 2014
JSM Foot and Ankle
ISSN : 2475-9112
Launched : 2016
JSM Alzheimer's Disease and Related Dementia
ISSN : 2378-9565
Launched : 2014
Journal of Addiction Medicine and Therapy
ISSN : 2333-665X
Launched : 2013
Journal of Veterinary Medicine and Research
ISSN : 2378-931X
Launched : 2013
Annals of Public Health and Research
ISSN : 2378-9328
Launched : 2014
Annals of Orthopedics and Rheumatology
ISSN : 2373-9290
Launched : 2013
Journal of Clinical Nephrology and Research
ISSN : 2379-0652
Launched : 2014
Annals of Community Medicine and Practice
ISSN : 2475-9465
Launched : 2014
Annals of Biometrics and Biostatistics
ISSN : 2374-0116
Launched : 2013
JSM Clinical Case Reports
ISSN : 2373-9819
Launched : 2013
Journal of Cancer Biology and Research
ISSN : 2373-9436
Launched : 2013
Journal of Surgery and Transplantation Science
ISSN : 2379-0911
Launched : 2013
Journal of Dermatology and Clinical Research
ISSN : 2373-9371
Launched : 2013
JSM Gastroenterology and Hepatology
ISSN : 2373-9487
Launched : 2013
Annals of Nursing and Practice
ISSN : 2379-9501
Launched : 2014
JSM Dentistry
ISSN : 2333-7133
Launched : 2013
Author Information X